Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
Prezzo in differita. Tempo differito Nasdaq - 15/09 22:00:00
48.79 USD   -1.29%
24/06C4 THERAPEUTICS, INC.: Brookline Capital Management rimane Buy
MM
04/06C4 THERAPEUTICS, INC.: da HC Wainwright è Buy
MM
31/03C4 THERAPEUTICS, INC.: giudizio positivo da BMO Capital
MM
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su C4 THERAPEUTICS, INC.
15/09Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreem..
15/09Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agree..
14/09INSIDER SELL: C4 Therapeutics
12/08C4 THERAPEUTICS': Q2 Loss Narrows, Revenue Grows; Secures Orphan Drug Designati..
11/08C4 THERAPEUTICS: Management's Discussion and Analysis of Financial Condition an..
11/08C4 THERAPEUTICS: Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a ..
11/08C4 THERAPEUTICS, INC.: Results of Operations and Financial Condition, Regulatio..
11/08C4 THERAPEUTICS: Reports Recent Business Highlights and Second Quarter 2021 Fin..
11/08C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Tre..
11/08C4 Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the..
11/08C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Tre..
11/08C4 Therapeutics Says CFT7455 Gets Orphan Drug Designation for Multiple Myelom..
25/06C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) dropped from Russell 2000 Value Index
25/06C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) dropped from Russell 2500 Value Index
25/06C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) dropped from Russell 3000E Value Index
25/06C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) dropped from Russell 3000 Value Index
25/06C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) dropped from Russell Small Cap Comp Value..
21/06C4 THERAPEUTICS: Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrade..
21/06C4 THERAPEUTICS, INC.: Submission of Matters to a Vote of Security Holders, Reg..
21/06C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of ..
21/06C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrad..
21/06C4 Therapeutics, Inc. Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 ..
17/06C4 THERAPEUTICS: Prices Common Stock Offering at $37 Per Share
17/06C4 Therapeutics Announces Pricing of Public Offering
15/06UPDATE: C4 Therapeutics Starts 4.25 Million Shares Offering -- Stock Down 10% i..
14/06C4 Therapeutics Starts 4.25 Million Shares Offering -- Stock Down 4% After-Ho..
14/06C4 THERAPEUTICS: Announces First Patient Dosed in Phase 1/2 Clinical Trial Eval..
14/06C4 THERAPEUTICS, INC.: Other Events, Financial Statements and Exhibits (form 8-..
14/06C4 Therapeutics Launches Proposed Public Offering
14/06C4 THERAPEUTICS: Doses First Patient in Study of Potential Multiple Myeloma, No..
14/06C4 THERAPEUTICS: Announces First Patient Dosed in Phase 1/2 Clinical Trial Eval..
14/06C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Eva..
07/06C4 THERAPEUTICS: Pre-clinical Data Support Plans to Advance CFT8919 to Clinical..
07/06C4 THERAPEUTICS, INC.: Other Events, Financial Statements and Exhibits (form 8-..
07/06C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader o..
07/06C4 Therapeutics, Inc. Presents Pre-Clinical Data on CFT8919
07/06C4 THERAPEUTICS: CFT8919 Pre-Clinical Data
26/05C4 THERAPEUTICS: CFT8919 Pre-clinical Data on EGFR L858R-driven NSCLC to be Pre..
26/05C4 THERAPEUTICS, INC.: Regulation FD Disclosure, Financial Statements and Exhib..
26/05C4 THERAPEUTICS: Plans to Pursue IND-Enabling Studies for Lung Cancer Drug
26/05C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into ..
26/05C4 Therapeutics, Inc. to Advance CFT8919, A Selective Degrader of EGFR L858R,..
20/05C4 THERAPEUTICS, INC.: Change in Directors or Principal Officers, Financial Sta..
20/05C4 THERAPEUTICS: Brings in Novartis Executive as New CFO
20/05C4 Therapeutics Appoints Lauren White as Chief Financial Officer
20/05C4 Therapeutics, Inc. Changes in Chief Financial Officer, Effective June 21, ..
13/05C4 THERAPEUTICS: Management's Discussion and Analysis of Financial Condition an..
13/05C4 THERAPEUTICS, INC.: Results of Operations and Financial Condition, Financial..
13/05C4 THERAPEUTICS: Reports Recent Business Highlights and First Quarter 2021 Fina..
13/05C4 Therapeutics Reports Consolidated Earnings Results for the Three Months En..
12/05C4 Therapeutics to Present at Upcoming Investor Conferences
30/04C4 THERAPEUTICS, INC.: Change in Directors or Principal Officers (form 8-K)
30/04Laura J. Wahlberg to Resign from C4 Therapeutics, Inc. as Vice President, Fin..
10/04C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrade..
10/04C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrade..
31/03Certain Warrants of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement ..
31/03Certain Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement E..
31/03Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreem..
22/03C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) added to S&P Global BMI Index
22/03C4 THERAPEUTICS, INC.(NASDAQGS: CCCC) added to S&P Biotechnology Select Industr..
11/03C4 THERAPEUTICS: Management's Discussion and Analysis of Financial Condition an..
11/03C4 Therapeutics, Inc. Elects Glenn Dubin as A Director
11/03C4 THERAPEUTICS, INC.: Results of Operations and Financial Condition, Change in..
11/03C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financi..
11/03C4 Therapeutics Reports Consolidated Earnings Results for the Full Year Ended..
10/03C4 Therapeutics to Present on the Discovery and Preclinical Development of CF..
24/02C4 Therapeutics to Participate in Upcoming March Investor Conferences
11/02C4 Therapeutics to Participate in BMO BioPharma Spotlight Series
19/01C4 THERAPEUTICS': Investigational New Drug Application for CFT7455 to Treat Blo..
19/01C4 Therapeutics Announces FDA Clearance of Investigational New Drug Applicati..
19/01C4 Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug App..
12/01C4 THERAPEUTICS, INC.: Regulation FD Disclosure, Financial Statements and Exhib..
07/01C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conferen..
06/01C4 THERAPEUTICS, INC.: Regulation FD Disclosure (form 8-K)
06/01C4 THERAPEUTICS: Sets Key Milestones for 2021
1  2Pross.
Prossimi eventi del settore